Market Overview

UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
Lilly to continue late-stage evacetrapib study; results expected mid-2016 (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Underperform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $36.00 to $43.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Eli Lilly & Co. closed on Tuesday at $52.80.

Latest Ratings for LLY

DateFirmActionFromTo
Jul 2015Leerink SwannMaintainsOutperform
Jul 2015SunTrust Robinson HumphreyMaintainsBuy
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Get Benzinga's Newsletters